Literature DB >> 24793049

Novel drug mechanisms in development for heart failure.

Soidjon D Khodjaev1, John R Teerlink, Fady I Malik.   

Abstract

Heart failure therapy has seen many advances over the last 40 years and has rapidly expanded beyond diuretics and digoxin to include several new mechanisms of action and devices whose efficacy had been demonstrated in large clinical trials. The evidence for their use is thoroughly summarized and discussed in current heart failure treatment guidelines and is not the subject of this review. Despite these advances, the mortality and morbidity in heart failure patients is still substantial, and there remains a need to develop new heart failure therapies. Recognizing that advances in medical therapy are often driven by the introduction of drugs with novel mechanisms of action, here we provide an overview of investigative heart failure drugs with novel mechanisms of action that are the subject of ongoing clinical trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24793049     DOI: 10.1007/s00424-014-1528-9

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  41 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

Review 2.  Molecular biology of the natriuretic peptide system: implications for physiology and hypertension.

Authors:  David G Gardner; Songcang Chen; Denis J Glenn; Chris L Grigsby
Journal:  Hypertension       Date:  2007-02-05       Impact factor: 10.190

3.  Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.

Authors:  Bradley P Morgan; Alexander Muci; Pu-Ping Lu; Xiangping Qian; Todd Tochimoto; Whitney W Smith; Marc Garard; Erica Kraynack; Scott Collibee; Ion Suehiro; Adam Tomasi; S Corey Valdez; Wenyue Wang; Hong Jiang; James Hartman; Hector M Rodriguez; Raja Kawas; Sheila Sylvester; Kathleen A Elias; Guillermo Godinez; Kenneth Lee; Robert Anderson; Sandra Sueoka; Donghong Xu; Zhengping Wang; Nebojsa Djordjevic; Fady I Malik; David J Morgans
Journal:  ACS Med Chem Lett       Date:  2010-08-20       Impact factor: 4.345

4.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

5.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Authors:  John R Teerlink; Cyril P Clarke; Khalil G Saikali; Jacqueline H Lee; Michael M Chen; Rafael D Escandon; Lyndsey Elliott; Rachel Bee; Mohammad Reza Habibzadeh; Jonathan H Goldman; Nelson B Schiller; Fady I Malik; Andrew A Wolff
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

6.  Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Authors:  You-Tang Shen; Fady I Malik; Xin Zhao; Christophe Depre; Sunil K Dhar; Patricio Abarzúa; David J Morgans; Stephen F Vatner
Journal:  Circ Heart Fail       Date:  2010-05-24       Impact factor: 8.790

7.  Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Authors:  Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Journal:  J Clin Pharmacol       Date:  2009-11-23       Impact factor: 3.126

8.  Renal and systemic effects of urodilatin in rats with high-output heart failure.

Authors:  Z A Abassi; J R Powell; E Golomb; H R Keiser
Journal:  Am J Physiol       Date:  1992-04

9.  Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.

Authors:  Lars Bärfacker; Alexander Kuhl; Alexander Hillisch; Rolf Grosser; Santiago Figueroa-Pérez; Heike Heckroth; Adam Nitsche; Jens-Kerim Ergüden; Heike Gielen-Haertwig; Karl-Heinz Schlemmer; Joachim Mittendorf; Holger Paulsen; Johannes Platzek; Peter Kolkhof
Journal:  ChemMedChem       Date:  2012-07-12       Impact factor: 3.466

10.  Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  Eur J Heart Fail       Date:  2013-04-05       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.